Drug maker Bayer AG and biotech venture-capital firm Versant Ventures are investing $225-million to create a Toronto-based stem-cell research company, a move with the potential to establish Canada as a global centre for the commercialization of regenerative-medicine therapies.
No comments:
Post a Comment